Clinical Trials Logo

Filter by:
NCT ID: NCT05207007 Completed - Clinical trials for Congenital Cataract Polar Posterior

Visual Function in Pediatric Patients With Posterior Lens Opacities

Start date: January 4, 2020
Study type: Observational

Prognostic factors determining visual outcomes in patients with posterior polar cataracts and posterior lenticonus are largely unknown. In this trial, the investigators aimed to evaluate the visual outcomes in patients with posterior polar cataracts and posterior lenticonus and try to find out the factors associated with the visual acuity after surgery. Patients enrolled in this study will be followed for at least 6 months and will have study visits at 1 day, 1 week, 1 month, 3 month, 6 month postoperatively.

NCT ID: NCT05206890 Not yet recruiting - Ovarian Cancer Clinical Trials

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Start date: January 14, 2022
Study type: Observational [Patient Registry]

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.

NCT ID: NCT05206799 Not yet recruiting - Child Clinical Trials

The CMCPCTH Research in Chinese Children

Start date: January 15, 2022
Study type: Observational

To obtain hemorrhage rate after coblation tonsillectomy, and to investigate risk factors of hemorrhage after coblation tonsillectomy in children.

NCT ID: NCT05206656 Recruiting - Clinical trials for Metastatic Breast Cancer

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Start date: October 9, 2020
Phase: Phase 2
Study type: Interventional

Eribulin is the promising agent for late-line metastatic breast cancer patients. The aim of this Phase II, double-arm, open-label and prospective clinical trial is to assess the efficacy and safety of Eribullin or Eribulin combined with Anlotinib in patients with metastatic breast cancer

NCT ID: NCT05206643 Recruiting - Clinical trials for Cardiovascular Diseases

Shanghai Pudong Population-based Cohort Establishment and Follow-up

Start date: August 7, 2019
Study type: Observational

Our objective is to establish a natural population-based cohort in East China based on the latest scientific researches, preliminary findings of the project team, and a close cooperation model of the Specialist Medical Consortium. Firstly, we will focus on the information and management status of high-risk, single-patient, and co-occurring patient groups of cardio cerebral diseases such as coronary heart disease and stroke. We plan to integrate the questionnaire data and sample database information into the cardio-cerebral "co-prevention and management" information platform, in order to establish a cardiovascular and cerebrovascular disease management system. Secondly, we aim to develop a new risk prediction model for heart and brain diseases based on the big data platform, lead the establishment of the "co-prevention and management" innovation management model for cardio cerebral diseases, and explore an integrated and innovative health management model for the prevention and treatment of cardio cerebral diseases for China.

NCT ID: NCT05206084 Not yet recruiting - Clinical trials for Coronary Artery Disease

A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

Start date: January 2022
Phase: N/A
Study type: Interventional

A prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared to the Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE).

NCT ID: NCT05206071 Recruiting - Clinical trials for Non-hodgkin's Lymphoma

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.

NCT ID: NCT05206032 Recruiting - Clinical trials for Acute Aortic Dissection

Blood Biomarker Discovery by Raman Spectroscopy in Acute Aortic Dissection

Start date: December 1, 2021
Study type: Observational

This study intends to collect about 500 cases of blood samples from acute aortic dissection (AAD) and other acute chest pain diseases (eg, AMI, PE, or angina).The investigators tend to detect Raman metabolic profile of blood samples collected from AAD and other control groups using the Raman spectroscopy. The data collected will be analyzed and used to create a Raman database able to provide a classification model based on machine learning. The investigators then compared them with healthy participants to evaluate the diagnostic performance of different levels of Raman metabolic profile at discriminating AAD from other diagnoses and assess whether Raman metabolic profile is a potential novel biomarker for AAD under different circumstances.

NCT ID: NCT05206019 Not yet recruiting - HIV/AIDS Clinical Trials

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center,randomized,open, single-dose, parallel-design study, which will be only enrolled Chinese healthy volunteers.

NCT ID: NCT05205850 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Start date: February 2022
Phase: Phase 1/Phase 2
Study type: Interventional

In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。